Proprietary AI analyst is now available
- Public Comps
- Abbott
Abbott Valuation Multiples
Discover Abbott's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker and more.
Abbott Overview
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Founded
1900
HQ

Employees
115.0K
Website
Financials (LTM)
EV
$185B
Valuation Multiples
Start free trialAbbott Financials
Abbott reported last 12-month revenue of $47B and EBITDA of $12B.
In the same LTM period, Abbott generated $27B in gross profit, $12B in EBITDA, and $9B in net income.
Revenue (LTM)
Abbott P&L
In the most recent fiscal year, Abbott reported revenue of $44B and EBITDA of $12B.
Abbott is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 27%, and net margin of 20%.
Financial data powered by Morningstar, Inc.
Abbott Stock Performance
Abbott has current market cap of $158B, and enterprise value of $185B.
Market Cap Evolution
Abbott's stock price is $90.78.
Abbott share price increased by 6.1% in the last 30 days, and decreased by 33.3% in the last year.
Abbott has an EPS (earnings per share) of $5.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $185B | $158B | 4.4% | 6.1% | -11.6% | -33.3% | $5.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbbott Valuation Multiples
Abbott trades at 3.9x EV/Revenue multiple, and 14.9x EV/EBITDA.
EV / Revenue (LTM)
Abbott Financial Valuation Multiples
As of June 5, 2026, Abbott has market cap of $158B and EV of $185B.
Abbott has a P/E ratio of 17.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abbott Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abbott Margins & Growth Rates
Abbott grew revenue by 14% and EBITDA by 10% in the last fiscal year.
In the most recent fiscal year, Abbott reported gross margin of 56%, EBITDA margin of 27%, and net margin of 20%.
Abbott Margins
Abbott Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abbott Operational KPIs
Abbott's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Abbott's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abbott's Rule of X is 61% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Abbott Competitors
Abbott competitors include Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker, Medtronic, Siemens, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories and Siemens Healthineers.
Most Abbott public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 14.3x | 13.4x | 33.0x | 30.3x | |||
| 4.9x | 4.8x | 19.0x | 18.9x | |||
| 5.9x | 5.8x | 18.8x | 18.3x | |||
| 5.1x | 4.9x | 17.7x | 17.1x | |||
| 3.7x | 3.4x | 13.5x | 12.3x | |||
| 3.1x | 3.0x | 15.3x | 16.6x | |||
| 4.1x | 4.0x | 13.2x | 12.7x | |||
| 7.8x | 7.4x | 26.1x | 24.4x | |||
This data is available for Pro users. Sign up to see all Abbott competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Abbott
Abbott has acquired 13 companies to date.
Last acquisition by Abbott was on November 20th 2025. Abbott acquired Exact Sciences for $21B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Abbott
| Description | Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. | Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors. | Cardiovascular Systems, Inc. is a medical technology company commercializing atherectomy systems for peripheral and coronary artery disease. Traded on NASDAQ as CSII, its Diamondback 360 and Orion platforms address calcified lesions in PAD and CAD treatments. The Predator 360 peripheral orbital atherectomy system supports vessel preparation for stenting. Headquartered in St. Paul, Minnesota, CSI serves interventional cardiologists and vascular surgeons across the United States with over 700,000 procedures performed. | - | |
| HQ Country | |||||
| HQ City | Madison, WI | San Jose, CA | Saint Paul, MN | - | |
| Deal Date | 20 Nov 2025 | 5 Sep 2023 | 8 Feb 2023 | 2 Sep 2021 | |
| Valuation | $21B | undisclosed | $851M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Abbott acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Abbott
Abbott has invested in 4 companies to date.
Latest investment by Abbott was on May 12th 2026. Abbott invested in NVision Imaging Technologies in their $38M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Abbott
| Description | NVision Imaging Technologies is a biotech company advancing MRI diagnostics through hyperpolarized metabolite imaging. Their platform uses quantum spin alignment to visualize tumor metabolism in real-time without radiation. Based in Belmont, California, NVision's technology detects early cancer responses to chemotherapy. Clinical trials at Stanford University validate its use in prostate and breast imaging. Founded in 2015, the firm raised Series A funding to commercialize agents compatible with standard 3T MRI scanners. | WHOOP offers a wearable performance optimization system with the WHOOP Strap 3.0 that monitors physiological data continuously. It tracks strain, recovery, and sleep for athletes, coaches, and teams to optimize training, prevent injuries, and forecast performance. Boston-headquartered WHOOP serves elite sports professionals, military units, and fitness enthusiasts with actionable insights from 24/7 heart rate variability, respiratory rate, and resting heart rate metrics. | Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors. | Bigfoot Biomedical is a diabetes management company engineering automated insulin delivery systems. Raleigh, North Carolina-headquartered and founded in 2015, it develops cloud-connected pumps and pens using machine learning for dosing optimization. Backed by Abbott, the subscription-based ecosystem targets type 1 patients, with FDA-cleared Unity system integrating continuous glucose monitors. | |
| HQ Country | |||||
| HQ City | Ulm | Boston, MA | San Jose, CA | San Jose, CA | |
| Deal Date | 12 May 2026 | 30 Mar 2026 | 13 Jan 2020 | 21 Mar 2018 | |
| Round | Series B | Series G | Series C | Series B | |
| Raised | $38M | $575M | $55M | $18M | |
| Investors | Abbott; Entrée Capital; Matterwave Ventures; Playground Global | Macquarie Capital; Qatar Investment Authority; 2PointZero; Craig Shapiro; Mayo Clinic; Promus Ventures; Mubadala Capital Ventures; Tom Loverro; Rory McIlroy; Abbott; Accomplice; Mathieu van der Poel | Abbott; Cormorant Asset Management; Janus Henderson Investors; Quadrant Capital Advisors; Senvest Capital; Smile Group | Abbott; Cormorant Asset Management; Janus Capital Group; JDRF T1D Fund; Quadrant Capital Advisors; Senvest Capital; Visionnaire Ventures; Xplorer Capital | |
| Valuation | undisclosed | $10B | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Abbott investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abbott
| When was Abbott founded? | Abbott was founded in 1900. |
| Where is Abbott headquartered? | Abbott is headquartered in United States. |
| How many employees does Abbott have? | As of today, Abbott has over 115K employees. |
| Who is the CEO of Abbott? | Abbott's CEO is Robert B. Ford. |
| Is Abbott publicly listed? | Yes, Abbott is a public company listed on NYSE. |
| What is the stock symbol of Abbott? | Abbott trades under ABT ticker. |
| When did Abbott go public? | Abbott went public in 1949. |
| Who are competitors of Abbott? | Abbott main competitors include Intuitive Surgical, Thermo Fisher Scientific, Danaher, Stryker, Medtronic, Siemens, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers. |
| What is the current market cap of Abbott? | Abbott's current market cap is $158B. |
| What is the current revenue of Abbott? | Abbott's last 12 months revenue is $47B. |
| What is the current revenue growth of Abbott? | Abbott revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Abbott? | Current revenue multiple of Abbott is 3.9x. |
| What is the current EBITDA of Abbott? | Abbott's last 12 months EBITDA is $12B. |
| What is Abbott's EBITDA margin? | Abbott's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Abbott? | Current EBITDA multiple of Abbott is 14.9x. |
| What is the current FCF of Abbott? | Abbott's last 12 months FCF is $9B. |
| What is Abbott's FCF margin? | Abbott's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Abbott? | Current FCF multiple of Abbott is 20.8x. |
| How many companies Abbott has acquired to date? | As of June 2026, Abbott has acquired 13 companies. |
| What was the largest acquisition by Abbott? | $25B acquisition of St. Jude Medical on 28th April 2016 was the largest M&A Abbott has done to date. |
| What companies Abbott acquired? | Abbott acquired St. Jude Medical, Exact Sciences, Alere, CFR Pharmaceuticals, Cardiovascular Systems, Veropharm, Tendyne Holdings, Topera, Cephea Valve Technologies, Walk Vascular, and 3 other companies. |
| In how many companies Abbott has invested to date? | As of June 2026, Abbott has invested in 4 companies. |
| What was the last Abbott investment? | On 12th May 2026 Abbott invested in NVision Imaging Technologies, participating in a $38M Series B round, alongside Entrée Capital, Matterwave Ventures, and Playground Global. |
| In what companies Abbott invested in? | Abbott invested in WHOOP, Bigfoot Biomedical, NVision Imaging Technologies, and SetPoint Medical. |
See public comps similar to Abbott
Lists including Abbott
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

